SightGlass Vision receives Breakthrough Device Designation from FDA for DOT spectacle lenses
SightGlass Vision, a joint venture of CooperCompanies and EssilorLuxottica, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to its Diffusion Optics Technology (DOT) spectacle lenses, which are intended to slow myopia progression in children.